期刊
JOURNAL OF PHARMACOLOGICAL SCIENCES
卷 137, 期 4, 页码 359-365出版社
JAPANESE PHARMACOLOGICAL SOC
DOI: 10.1016/j.jphs.2018.06.014
关键词
Myeloid-derived suppressor cell; Valproic acid; Immunosuppression; Interleukin-4 receptor-alpha; Programmed cell death 1 ligand 1
资金
- SEI Group CSR Foundation
- Mishima Kaiun Memorial Foundation
- SENSHIN Medical Research Foundation
- Takeda Science Foundation (Japan)
- Platform Project for Supporting Drug Discovery and Life Science Research - Japan Agency for Medical Research and Development [AMED] [18am0101084j0002]
Immune checkpoint blockade (ICB) is a promising novel therapy for multiple cancer types; however, most patients show limited or no clinical response. Accumulating evidence indicates that myeloid-derived suppressor cells (MDSCs) are a major factor responsible for immunosuppression in patients with cancer. Therefore, identifying effective therapies that deplete or modulate MDSCs is essential. In this study, we focus on the anticonvulsant drug valproic acid (VPA), which has additional activities including anticancer and immunoregulation by inhibition of histone deacetylases. We showed that VPA decreased the proportion of polymorphonuclear (PMN)-MDSCs in vitro and showed for the first time that VPA greatly attenuated the immunosuppressive function of MDSCs in a dose-dependent manner. Moreover, we demonstrated that in vitro differentiated VPA-conditioned MDSCs exhibited impaired ability to stimulate tumor progression in vivo. We also showed the possible involvement of several mechanisms in the VPA-induced attenuation of the immunosuppressive function of MDSCs, including the interleukin-4 receptor-a (IL-4R alpha)/arginase axis, programmed cell death 1 ligand 1 (PD-L1) and toll-like receptor 4 (TLR4) signaling pathways, and retinoblastoma 1 (Rb1) derepression. This research highlights the potential of combining VPA with ICB in cancer treatment. (c) 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据